OCUL
Ocular Therapeutix, Inc.
Price Chart
Latest Quote
$10.10
+0.13 (+1.30%)
Current Price
| Previous Close | $9.97 |
| Open | $9.83 |
| Day High | $10.59 |
| Day Low | $9.80 |
| Volume | 733,877 |
Stock Information
| Shares Outstanding | 218.96M |
| Total Debt | $79.46M |
| Cash Equivalents | $666.70M |
| Revenue | $52.04M |
| Net Income | $-290.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.21B |
| EPS (TTM) | $-1.44 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.60B |
| Sales | $52.04M |
| Income | $-290.50M |
| Book/sh | $2.66 |
| Cash/sh | $3.04 |
| Employees | 325 |
Financial Ratios
| Quick Ratio | 14.49 |
| Current Ratio | 14.81 |
| Debt/Eq | 13.66 |
Returns & Margins
| ROA | -32.88% |
| ROE | -68.55% |
| Operating Margin | -865.46% |
Ownership
| Insider Ownership | 0.94% |
| Institutional Ownership | 95.67% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.57 |
| P/S | 42.50 |
| P/B | 3.80 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $26.91 |
Technical Indicators
| SMA20 | $8.89 |
| SMA50 | $9.06 |
| SMA200 | $10.49 |
| RSI | 74.39 |
| ATR | 0.5789 |
| Shares Float | 184.40M |
| Short Float | 13.53% |
| Short Ratio | 8.74 |
| Volatility | 0.90 |
| Rel Volume | 0.26 |
Performance History
| Week | +12.35% |
| Month | +22.87% |
| Quarter | +24.69% |
| 6 Months | -22.19% |
| YTD | -14.55% |
| Year | +24.23% |
| 3 Years | +103.22% |
| 5 Years | -25.84% |
| 10 Years | +86.69% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $10.10 | 733,877 |
| 2026-06-22 | $9.97 | 5,161,800 |
| 2026-06-18 | $9.43 | 6,114,300 |
| 2026-06-17 | $9.64 | 7,404,000 |
| 2026-06-16 | $8.94 | 2,329,700 |
| 2026-06-15 | $8.99 | 2,467,200 |
| 2026-06-12 | $8.94 | 2,696,300 |
| 2026-06-11 | $8.70 | 2,765,400 |
| 2026-06-10 | $8.74 | 2,666,700 |
| 2026-06-09 | $8.47 | 2,426,900 |
| 2026-06-08 | $8.16 | 1,502,400 |
| 2026-06-05 | $8.25 | 1,348,700 |
| 2026-06-04 | $8.80 | 1,824,200 |
| 2026-06-03 | $8.35 | 2,044,900 |
| 2026-06-02 | $8.31 | 3,053,200 |
| 2026-06-01 | $8.93 | 2,064,900 |
| 2026-05-29 | $9.01 | 2,403,500 |
| 2026-05-28 | $9.15 | 3,385,900 |
| 2026-05-27 | $8.54 | 2,569,300 |
| 2026-05-26 | $8.29 | 2,041,700 |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
đ° Latest News
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
StockStory âĸ 2026-06-18T15:17:28Z
Why Ocular Therapeutix (OCUL) Stock Is Up Today
StockStory âĸ 2026-06-17T18:28:51Z
OCUL Stock Is Climbing Ahead Of Investor Day â What Is On The Agenda?
Stocktwits âĸ 2026-06-17T16:09:10Z
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-15T20:30:02Z
3 of Wall Streetâs Favorite Stocks That Concern Us
StockStory âĸ 2026-06-10T09:21:28Z
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility
Simply Wall St. âĸ 2026-06-05T19:11:15Z
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
StockStory âĸ 2026-05-28T16:14:27Z
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Motley Fool âĸ 2026-05-26T22:26:41Z
What This Fundâs $14 Million Ocular Therapeutix Exit Could Signal for Investors
Motley Fool âĸ 2026-05-19T17:26:23Z
3 Stocks Under $10 That Fall Short
StockStory âĸ 2026-05-15T15:00:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,574,000 | $5,626,000 | $5,281,000 | $4,540,000 |
| Cost Of Revenue | $6,574,000 | $5,626,000 | $5,281,000 | $4,540,000 |
| Total Revenue | $51,951,000 | $63,723,000 | $58,443,000 | $51,494,000 |
| Operating Revenue | $51,951,000 | $63,723,000 | $58,443,000 | $51,494,000 |
| Expenses | ||||
| Interest Expense | $11,835,000 | $13,577,000 | $11,338,000 | $7,022,000 |
| Total Expenses | $321,968,000 | $235,504,000 | $140,825,000 | $130,148,000 |
| Other Income Expense | $-2,442,000 | $-28,430,000 | $9,001,000 | $13,840,000 |
| Other Non Operating Income Expenses | $29,000 | - | $-1,000 | $-1,000 |
| Net Non Operating Interest Income Expense | $6,520,000 | $6,705,000 | $-7,355,000 | $-6,224,000 |
| Interest Expense Non Operating | $11,835,000 | $13,577,000 | $11,338,000 | $7,022,000 |
| Operating Expense | $315,394,000 | $229,878,000 | $135,544,000 | $125,608,000 |
| Selling And Marketing Expense | $6,148,000 | $5,115,000 | $4,828,000 | $4,166,000 |
| General And Administrative Expense | $112,150,000 | $97,128,000 | $69,661,000 | $67,980,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Net Interest Income | $6,520,000 | $6,705,000 | $-7,355,000 | $-6,224,000 |
| Interest Income | $18,355,000 | $20,282,000 | $3,983,000 | $798,000 |
| Normalized Income | $-263,468,000 | $-165,076,000 | $-89,738,000 | $-84,879,000 |
| Net Income From Continuing And Discontinued Operation | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Total Operating Income As Reported | $-270,017,000 | $-171,781,000 | $-82,382,000 | $-78,654,000 |
| Net Income Common Stockholders | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Net Income | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Net Income Including Noncontrolling Interests | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Net Income Continuous Operations | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Pretax Income | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
| Special Income Charges | $0 | $-27,950,000 | $14,190,000 | $0 |
| Interest Income Non Operating | $18,355,000 | $20,282,000 | $3,983,000 | $798,000 |
| Operating Income | $-270,017,000 | $-171,781,000 | $-82,382,000 | $-78,654,000 |
| Gross Profit | $45,377,000 | $58,097,000 | $53,162,000 | $46,954,000 |
| Average Dilution Earnings | - | - | $-6,233,000 | $-9,245,000 |
| Per Share | ||||
| Diluted EPS | $-1.42 | $-1.22 | $-1.02 | $-0.97 |
| Basic EPS | $-1.42 | $-1.22 | $-1.01 | $-0.92 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-247,310,000 | $-147,713,000 | $-75,417,000 | $-75,748,000 |
| Total Unusual Items | $-2,471,000 | $-28,430,000 | $9,002,000 | $13,841,000 |
| Total Unusual Items Excluding Goodwill | $-2,471,000 | $-28,430,000 | $9,002,000 | $13,841,000 |
| Reconciled Depreciation | $4,323,000 | $3,786,000 | $2,983,000 | $2,109,000 |
| EBITDA (Bullshit earnings) | $-249,781,000 | $-176,143,000 | $-66,415,000 | $-61,907,000 |
| EBIT | $-254,104,000 | $-179,929,000 | $-69,398,000 | $-64,016,000 |
| Diluted Average Shares | $187,241,483 | $158,265,162 | $85,596,594 | $82,644,267 |
| Basic Average Shares | $187,241,483 | $158,265,162 | $79,827,362 | $76,875,035 |
| Diluted NI Availto Com Stockholders | $-265,939,000 | $-193,506,000 | $-86,969,000 | $-80,283,000 |
| Gain On Sale Of Security | $-2,471,000 | $-480,000 | $-5,188,000 | $13,841,000 |
| Research And Development | $197,096,000 | $127,635,000 | $61,055,000 | $53,462,000 |
| Selling General And Administration | $118,298,000 | $102,243,000 | $74,489,000 | $72,146,000 |
| Other Gand A | $35,408,000 | $29,279,000 | $20,871,000 | $23,074,000 |
| Salaries And Wages | $76,742,000 | $67,849,000 | $48,790,000 | $44,906,000 |
| Other Special Charges | - | $27,950,000 | $-14,190,000 | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $654,310,000 | $315,344,000 | $91,131,000 | $35,379,000 |
| Total Assets | $808,057,000 | $457,935,000 | $252,060,000 | $149,289,000 |
| Total Non Current Assets | $25,928,000 | $16,948,000 | $19,825,000 | $19,662,000 |
| Other Non Current Assets | $1,614,000 | $1,614,000 | $1,614,000 | $1,764,000 |
| Current Assets | $782,129,000 | $440,987,000 | $232,235,000 | $129,627,000 |
| Other Current Assets | $10,855,000 | $13,457,000 | $7,794,000 | $4,028,000 |
| Inventory | $3,564,000 | $3,040,000 | $2,305,000 | $1,974,000 |
| Receivables | $30,650,000 | $32,388,000 | $26,179,000 | $21,325,000 |
| Accounts Receivable | $30,650,000 | $32,388,000 | $26,179,000 | $21,325,000 |
| Cash Cash Equivalents And Short Term Investments | $737,060,000 | $392,102,000 | $195,807,000 | $102,300,000 |
| Cash And Cash Equivalents | $737,060,000 | $392,102,000 | $195,807,000 | $102,300,000 |
| Restricted Cash | - | $0 | $150,000 | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $76,968,000 | $75,783,000 | $83,389,000 | $64,283,000 |
| Long Term Debt And Capital Lease Obligation | $74,151,000 | $73,850,000 | $81,803,000 | $62,684,000 |
| Long Term Debt | $71,336,000 | $68,505,000 | $74,925,000 | $54,006,000 |
| Current Debt And Capital Lease Obligation | $2,817,000 | $1,933,000 | $1,586,000 | $1,599,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $153,747,000 | $142,591,000 | $160,929,000 | $113,910,000 |
| Total Non Current Liabilities Net Minority Interest | $102,941,000 | $101,237,000 | $126,033,000 | $82,515,000 |
| Other Non Current Liabilities | $887,000 | $141,000 | $108,000 | $93,000 |
| Derivative Product Liabilities | $13,903,000 | $13,246,000 | $29,987,000 | $6,351,000 |
| Non Current Deferred Liabilities | $14,000,000 | $14,000,000 | $14,135,000 | $13,387,000 |
| Current Liabilities | $50,806,000 | $41,354,000 | $34,896,000 | $31,395,000 |
| Current Deferred Liabilities | $0 | $128,000 | $255,000 | $576,000 |
| Payables And Accrued Expenses | $47,989,000 | $39,293,000 | $33,055,000 | $29,220,000 |
| Interest Payable | $754,000 | $592,000 | $11,689,000 | $8,756,000 |
| Payables | $4,154,000 | $4,176,000 | $4,389,000 | $5,123,000 |
| Accounts Payable | $4,154,000 | $4,176,000 | $4,389,000 | $5,123,000 |
| Equity | ||||
| Common Stock Equity | $654,310,000 | $315,344,000 | $91,131,000 | $35,379,000 |
| Total Equity Gross Minority Interest | $654,310,000 | $315,344,000 | $91,131,000 | $35,379,000 |
| Stockholders Equity | $654,310,000 | $315,344,000 | $91,131,000 | $35,379,000 |
| Retained Earnings | $-1,157,023,000 | $-891,084,000 | $-697,578,000 | $-616,842,000 |
| Other | ||||
| Ordinary Shares Number | $215,927,600 | $157,749,490 | $114,963,193 | $77,201,819 |
| Share Issued | $215,927,600 | $157,749,490 | $114,963,193 | $77,201,819 |
| Tangible Book Value | $654,310,000 | $315,344,000 | $91,131,000 | $35,379,000 |
| Invested Capital | $725,646,000 | $383,849,000 | $166,056,000 | $89,385,000 |
| Working Capital | $731,323,000 | $399,633,000 | $197,339,000 | $98,232,000 |
| Capital Lease Obligations | $5,632,000 | $7,278,000 | $8,464,000 | $10,277,000 |
| Total Capitalization | $725,646,000 | $383,849,000 | $166,056,000 | $89,385,000 |
| Additional Paid In Capital | $1,811,311,000 | $1,206,412,000 | $788,697,000 | $652,213,000 |
| Capital Stock | $22,000 | $16,000 | $12,000 | $8,000 |
| Common Stock | $22,000 | $16,000 | $12,000 | $8,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $14,000,000 | $14,000,000 | $14,135,000 | $13,387,000 |
| Long Term Capital Lease Obligation | $2,815,000 | $5,345,000 | $6,878,000 | $8,678,000 |
| Current Deferred Revenue | $0 | $128,000 | $255,000 | $576,000 |
| Current Capital Lease Obligation | $2,817,000 | $1,933,000 | $1,586,000 | $1,599,000 |
| Current Accrued Expenses | $43,835,000 | $35,117,000 | $28,666,000 | $24,097,000 |
| Net PPE | $24,314,000 | $15,334,000 | $18,211,000 | $17,898,000 |
| Accumulated Depreciation | $-27,520,000 | $-23,632,000 | $-20,260,000 | $-17,278,000 |
| Gross PPE | $51,834,000 | $38,966,000 | $38,471,000 | $35,176,000 |
| Leases | $15,280,000 | $14,528,000 | $14,699,000 | $9,074,000 |
| Construction In Progress | $10,256,000 | $119,000 | $281,000 | $4,071,000 |
| Other Properties | $24,700,000 | $22,727,000 | $21,987,000 | $20,527,000 |
| Machinery Furniture Equipment | $1,598,000 | $1,592,000 | $1,504,000 | $1,504,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,641,000 | $1,337,000 | $991,000 | $766,000 |
| Work In Process | $1,721,000 | $1,489,000 | $1,012,000 | $899,000 |
| Raw Materials | $202,000 | $214,000 | $302,000 | $309,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-216,893,000 | $-135,965,000 | $-76,321,000 | $-63,318,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-204,883,000 | $-134,677,000 | $-70,234,000 | $-59,603,000 |
| Cash Flow From Continuing Operating Activities | $-204,883,000 | $-134,677,000 | $-70,234,000 | $-59,603,000 |
| Operating Gains Losses | $2,442,000 | $28,430,000 | $-9,001,000 | $-13,840,000 |
| Investing Activities | ||||
| Capital Expenditure | $-12,010,000 | $-1,288,000 | $-6,087,000 | $-3,715,000 |
| Investing Cash Flow | $-11,880,000 | $-1,288,000 | $-6,087,000 | $-3,715,000 |
| Cash Flow From Continuing Investing Activities | $-11,880,000 | $-1,288,000 | $-6,087,000 | $-3,715,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $541,177,000 | $317,369,000 | $118,112,000 | $940,000 |
| Financing Cash Flow | $561,721,000 | $332,110,000 | $169,828,000 | $1,454,000 |
| Cash Flow From Continuing Financing Activities | $561,721,000 | $332,110,000 | $169,828,000 | $1,454,000 |
| Net Common Stock Issuance | $541,177,000 | $317,369,000 | $118,112,000 | $940,000 |
| Common Stock Issuance | $541,177,000 | $317,369,000 | $118,112,000 | $940,000 |
| Net Other Financing Charges | - | - | $-5,184,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-28,125,000 | $0 |
| Issuance Of Debt | $0 | $0 | $84,474,000 | $0 |
| Interest Paid Supplemental Data | $9,029,000 | $21,533,000 | $5,464,000 | $2,147,000 |
| End Cash Position | $738,674,000 | $393,716,000 | $197,571,000 | $104,064,000 |
| Beginning Cash Position | $393,716,000 | $197,571,000 | $104,064,000 | $165,928,000 |
| Changes In Cash | $344,958,000 | $196,145,000 | $93,507,000 | $-61,864,000 |
| Proceeds From Stock Option Exercised | $20,544,000 | $14,741,000 | $551,000 | $514,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $56,349,000 | $0 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | $0 |
| Short Term Debt Payments | $0 | $0 | $-2,000,000 | $0 |
| Short Term Debt Issuance | $0 | $0 | $2,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $0 | $56,349,000 | $0 |
| Long Term Debt Payments | $0 | $0 | $-26,125,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $82,474,000 | $0 |
| Net PPE Purchase And Sale | $-11,880,000 | $-1,288,000 | $-6,087,000 | $-3,715,000 |
| Sale Of PPE | $130,000 | $0 | $0 | - |
| Purchase Of PPE | $-12,010,000 | $-1,288,000 | $-6,087,000 | $-3,715,000 |
| Change In Working Capital | $7,710,000 | $-10,230,000 | $-7,411,000 | $1,349,000 |
| Change In Other Working Capital | $-128,000 | $-262,000 | $427,000 | $963,000 |
| Change In Other Current Liabilities | $-1,646,000 | $-1,186,000 | $-1,813,000 | $2,729,000 |
| Change In Other Current Assets | $1,307,000 | $505,000 | $1,570,000 | $-3,175,000 |
| Change In Payables And Accrued Expense | $4,361,000 | $3,320,000 | $1,356,000 | $1,023,000 |
| Change In Accrued Expense | $5,248,000 | $3,638,000 | $773,000 | $1,644,000 |
| Change In Payable | $-887,000 | $-318,000 | $583,000 | $-621,000 |
| Change In Account Payable | $-887,000 | $-318,000 | $583,000 | $-621,000 |
| Change In Prepaid Assets | $2,602,000 | $-5,663,000 | $-3,766,000 | $723,000 |
| Change In Inventory | $-524,000 | $-735,000 | $-331,000 | $-724,000 |
| Change In Receivables | $1,738,000 | $-6,209,000 | $-4,854,000 | $-190,000 |
| Changes In Account Receivables | $1,738,000 | $-6,209,000 | $-4,854,000 | $-190,000 |
| Other Non Cash Items | $3,397,000 | $3,734,000 | $6,106,000 | $4,853,000 |
| Stock Based Compensation | $43,184,000 | $33,109,000 | $17,825,000 | $16,964,000 |
| Depreciation Amortization Depletion | $4,323,000 | $3,786,000 | $2,983,000 | $2,109,000 |
| Depreciation And Amortization | $4,323,000 | $3,786,000 | $2,983,000 | $2,109,000 |
| Gain Loss On Investment Securities | $2,471,000 | $480,000 | $5,188,000 | $-13,841,000 |
| Gain Loss On Sale Of PPE | $-29,000 | $0 | $1,000 | $1,000 |
| Net Income From Continuing Operations | $-265,939,000 | $-193,506,000 | $-80,736,000 | $-71,038,000 |
Fetched: 2026-06-22